Human Blood Serum Inhibits Ductal Carcinoma Cells BT474 Growth and Modulates Effect of HER2 Inhibition

Trastuzumab, a HER2-targeted antibody, is widely used for targeted therapy of HER2-positive breast cancer (BC) patients; yet, not all of them respond to this treatment. We investigated here whether trastuzumab activity on the growth of HER2-overexpressing BT474 cells may interfere with human periphe...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamashev, Dmitrii, Shaban, Nina, Suntsova, Maria, Raevskiy, Mikhail, Efimov, Victor, Moisseev, Aleksey, Sorokin, Maxim, Buzdin, Anton
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405390/
https://www.ncbi.nlm.nih.gov/pubmed/36009461
http://dx.doi.org/10.3390/biomedicines10081914

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405390/
https://www.ncbi.nlm.nih.gov/pubmed/36009461
http://dx.doi.org/10.3390/biomedicines10081914

Ejemplares similares